RxDoctor Payments Data

Latoya Bexley

Family · Carrollton, GANPI 1003190455

Payments from drug & device makers

$4,681in general payments, 2019–2025

Across 154 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$392
  • Esperion Therapeutics, Inc.$388
  • Amgen$180
  • Xeris Pharmaceuticals, Inc.$180
  • Insulet Corporation$159
  • plus $819 from 12 others

What the payments were for

  • Travel & lodging$1,62435%
  • Food & beverage$3,03165%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,681 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$49,336
Medicare patients
215
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide438$525,103
OzempicSemaglutide276$367,852
JardianceEmpagliflozin233$272,860
Humulin R U-500 KwikpenInsulin Regular, Human78$217,530
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog117$169,092
Tresiba Flextouch U-100Insulin Degludec137$109,922
Repatha SureclickEvolocumab107$99,802
FarxigaDapagliflozin Propanediol86$99,602
Tresiba Flextouch U-200Insulin Degludec63$89,691
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/754$67,942
Novolog FlexpenInsulin Aspart172$64,853
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt39$58,310
Humalog Kwikpen U-100Insulin Lispro113$45,558
Humalog Kwikpen U-200Insulin Lispro19$44,617
NovologInsulin Aspart103$33,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$130$570,583549 claims
Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi, Synjardy Xr$99$328,355274 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$78$28,16133 claims
AbbVieSynthroid$46$16,127160 claims
Esperion Therapeutics, Inc.Nexlizet$388$10,72519 claims
Kowa Pharmaceuticals America, Inc.Livalo$62$9,49914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →